The vaccination status and adverse effects of COVID-19 vaccine among pregnant women in Japan in 2021.


Journal

The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761

Informations de publication

Date de publication:
Jul 2022
Historique:
revised: 22 03 2022
received: 24 02 2022
accepted: 27 04 2022
pubmed: 11 5 2022
medline: 7 7 2022
entrez: 10 5 2022
Statut: ppublish

Résumé

To investigate the vaccination status and adverse reactions to the COVID-19 vaccine among pregnant women in Japan, we conducted an online questionnaire survey from October 5 to November 22, 2021. The number of participants in the online survey was 6576. Of the participants, 4840 (73.6%) were vaccinated twice, and 557 (8.5%) were vaccinated once. A total of 1179 (17.9%) responders had never been vaccinated against COVID-19. The most frequent adverse reaction was local pain at the injection site. The incidence of local adverse reactions was almost identical after the first and the second vaccinations, while systemic reactions, such as fever and fatigue/malaise, and adverse reactions outside the vaccination site such as headache and arthralgia, were more frequent after the second vaccination than after the first vaccination. Regarding the obstetrical complications, uterine tension and/or contraction was observed in 1.65% of the pregnant women after the first vaccination and in 2.98% after the second vaccination, and uterine pain appeared in 1.06% of the pregnant women after the second vaccination. However, serious symptoms, such as hemorrhage, decreased fetal movement, edema, increased blood pressure, and amniorrhexis, were seen in less than 1% of vaccinated women after both the first and second vaccinations. This study clarified the characteristics of vaccination, adverse reactions, and obstetrical symptoms in pregnant women in Japan who had the COVID-19 vaccine up to the second dose. As a booster vaccination is currently underway, further study is needed to improve the management of pregnant women during the current pandemic.

Identifiants

pubmed: 35537777
doi: 10.1111/jog.15285
pmc: PMC9347631
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1561-1569

Subventions

Organisme : Ministry of Health, Labor and Welfare of Japan
ID : 20CA2033
Organisme : Subcommittee on Perinatal Infection of the Committee on the Perinatal Period of Japan Society of Obstetrics and Gynecology

Informations de copyright

© 2022 Japan Society of Obstetrics and Gynecology.

Références

Nat Med. 2022 Mar;28(3):504-512
pubmed: 35027756
N Engl J Med. 2021 Jun 17;384(24):2273-2282
pubmed: 33882218
Lancet Reg Health Eur. 2022 Feb;13:100313
pubmed: 35098198
Front Glob Womens Health. 2021 Nov 01;2:761511
pubmed: 34816252
BMJ. 2020 Sep 1;370:m3320
pubmed: 32873575
J Korean Med Sci. 2021 May 31;36(21):e153
pubmed: 34060261

Auteurs

Shihoko Komine-Aizawa (S)

Division of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.

Yasuo Haruyama (Y)

Integrated Research Faculty for Advanced Medical Sciences, Dokkyo Medical University, Tochigi, Japan.

Masashi Deguchi (M)

Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan.

Satoshi Hayakawa (S)

Division of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.

Kei Kawana (K)

Division of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.

Gen Kobashi (G)

Department of Public Health, Dokkyo Medical University, Tochigi, Japan.

Etsuko Miyagi (E)

Department of Obstetrics and Gynecology, Yokohama City University Hospital, Yokohama, Japan.

Hideto Yamada (H)

Center for Recurrent Pregnancy Loss, Teine Keijinkai Hospital, Sapporo, Japan.

Takashi Sugiyama (T)

Department of Obstetrics and Gynecology, Ehime University Graduate School of Medicine, Toon, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH